AC Immune SA (NASDAQ:ACIU - Get Free Report) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 1,350,000 shares, an increase of 23.9% from the February 28th total of 1,090,000 shares. Based on an average daily volume of 182,400 shares, the short-interest ratio is presently 7.4 days. Currently, 2.2% of the shares of the stock are sold short.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of AC Immune in a research note on Thursday.
Check Out Our Latest Research Report on ACIU
AC Immune Stock Down 4.8 %
Shares of NASDAQ ACIU traded down $0.09 during midday trading on Friday, hitting $1.69. The stock had a trading volume of 37,104 shares, compared to its average volume of 327,589. AC Immune has a 1 year low of $1.68 and a 1 year high of $4.98. The company has a market capitalization of $169.19 million, a PE ratio of -3.66 and a beta of 1.49. The stock has a 50 day simple moving average of $2.42 and a 200-day simple moving average of $2.87.
Institutional Investors Weigh In On AC Immune
Hedge funds have recently modified their holdings of the business. Northern Trust Corp acquired a new stake in AC Immune in the 4th quarter valued at about $1,088,000. Renaissance Technologies LLC lifted its position in AC Immune by 14.6% during the fourth quarter. Renaissance Technologies LLC now owns 740,198 shares of the company's stock worth $1,999,000 after buying an additional 94,191 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in AC Immune by 130.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company's stock worth $355,000 after buying an additional 74,358 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in AC Immune in the 4th quarter valued at $118,000. Finally, Cantor Fitzgerald L. P. acquired a new stake in shares of AC Immune in the 4th quarter worth $68,000. 51.36% of the stock is currently owned by institutional investors and hedge funds.
About AC Immune
(
Get Free Report)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Articles
Before you consider AC Immune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.
While AC Immune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
